A recent SciTechDaily article discussed a promising new study out of the University of Michigan that could change the way we treat lymphoma. The oral drug zanubrutinib was used to combat a specific type of slow-growing cancer known as marginal zone lymphoma. Results showed that the drug shrank cancer in 80% of the 20 subjects, with a fifth of them going into complete remission.
Zanubrutinib is a novel drug known as a Bruton Tyrosine Kinase inhibitor that blocks a specific enzyme that allows lymphomas to survive and grow. The clinical trial’s results combined with a secondary study gained the drug FDA approval on a contingent basis for adults with that specific lymphoma that has otherwise been treated unsuccessfully.